Recent research has indicated that homozygosity for the ApoE3-R136S mutation can mitigate ApoE4-driven tau pathology, neurodegeneration, and neuroinflammation in mouse models of tauopathy and human induced pluripotent stem cell (iPSC)-derived neuron models (Figure 3). Here, MAPT is linked to tauopathy.